Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma

Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma

From 2001 to 2006, 11 patients with MVAC-treated metastatic urothelial carcinoma received as a second-line therapy GDC therapy consisting of gemcitabine (1,000 mg/m2) on day land 8, docetaxel (80 mg/m2) on day 1 and carboplatin (AUC 5) on day 1 in each 21-day cycle. The 11 patients received a total...

Description complète

Détails bibliographiques
Publié dans:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 54(2008), 9 vom: 23. Sept., Seite 581-5
Auteur principal: Inoue, Takamitsu (Auteur)
Autres auteurs: Obara, Takashi, Saito, Mitsuru, Kumazawa, Teruaki, Narita, Shintaro, Horikawa, Yohei, Yuasa, Takeshi, Tsuchiya, Norihiko, Satoh, Shigeru, Habuchi, Tomonori
Format: Article
Langue:Japanese
Publié: 2008
Accès à la collection:Hinyokika kiyo. Acta urologica Japonica
Sujets:Journal Article Taxoids Deoxycytidine 0W860991D6 Docetaxel 15H5577CQD Vinblastine 5V9KLZ54CY Doxorubicin 80168379AG plus... Carboplatin BG3F62OND5 Cisplatin Q20Q21Q62J Methotrexate YL5FZ2Y5U1 Gemcitabine
LEADER 01000caa a22002652c 4500
001 NLM184201411
003 DE-627
005 20250209214456.0
007 tu
008 231223s2008 xx ||||| 00| ||jpn c
028 5 2 |a pubmed25n0614.xml 
035 |a (DE-627)NLM184201411 
035 |a (NLM)18975570 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Inoue, Takamitsu  |e verfasserin  |4 aut 
245 1 0 |a Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma 
264 1 |c 2008 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 26.11.2008 
500 |a Date Revised 07.12.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a From 2001 to 2006, 11 patients with MVAC-treated metastatic urothelial carcinoma received as a second-line therapy GDC therapy consisting of gemcitabine (1,000 mg/m2) on day land 8, docetaxel (80 mg/m2) on day 1 and carboplatin (AUC 5) on day 1 in each 21-day cycle. The 11 patients received a total of 42 cycles. The median progression-free survival and the median overall survival were 3 months (range 0-51) and 10 months (range 2-51), respectively. The median overall survival from diagnosis of the metastasis was 13.0 months (range 7-55). Complete response and partial response rates were 1/11 (9%) and 5/11 (45%), respectively. One- and two-year survival rates were 36 and 9%, respectively. Grade 3 or 4 hematologic toxicity included neutropenia (69.0%), thrombocytopenia (47.6%) and anemia (45.2%). Non-hematologic toxicity of grade 3 or 4 consisted mainly of diarrhea (23.8%) and anorexia (21.4%). GDC regimen as a second-line chemotherapy was effective in 54% of patients with MVAC-treated metastatic urothelial carcinoma, although the high incidence of hematologic toxicities and short period of progression-free survival remain to be major problems 
650 4 |a Journal Article 
650 7 |a Taxoids  |2 NLM 
650 7 |a Deoxycytidine  |2 NLM 
650 7 |a 0W860991D6  |2 NLM 
650 7 |a Docetaxel  |2 NLM 
650 7 |a 15H5577CQD  |2 NLM 
650 7 |a Vinblastine  |2 NLM 
650 7 |a 5V9KLZ54CY  |2 NLM 
650 7 |a Doxorubicin  |2 NLM 
650 7 |a 80168379AG  |2 NLM 
650 7 |a Carboplatin  |2 NLM 
650 7 |a BG3F62OND5  |2 NLM 
650 7 |a Cisplatin  |2 NLM 
650 7 |a Q20Q21Q62J  |2 NLM 
650 7 |a Methotrexate  |2 NLM 
650 7 |a YL5FZ2Y5U1  |2 NLM 
650 7 |a Gemcitabine  |2 NLM 
700 1 |a Obara, Takashi  |e verfasserin  |4 aut 
700 1 |a Saito, Mitsuru  |e verfasserin  |4 aut 
700 1 |a Kumazawa, Teruaki  |e verfasserin  |4 aut 
700 1 |a Narita, Shintaro  |e verfasserin  |4 aut 
700 1 |a Horikawa, Yohei  |e verfasserin  |4 aut 
700 1 |a Yuasa, Takeshi  |e verfasserin  |4 aut 
700 1 |a Tsuchiya, Norihiko  |e verfasserin  |4 aut 
700 1 |a Satoh, Shigeru  |e verfasserin  |4 aut 
700 1 |a Habuchi, Tomonori  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 54(2008), 9 vom: 23. Sept., Seite 581-5  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnas 
773 1 8 |g volume:54  |g year:2008  |g number:9  |g day:23  |g month:09  |g pages:581-5 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 54  |j 2008  |e 9  |b 23  |c 09  |h 581-5